MKMasaya Koshizaka

Masaya Koshizaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masaya Koshizaka has a total of 289 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of Metabolic Dysfunction‐Associated Steatotic Liver Disease Between Individuals With Werner Syndrome and Those With Insulin‐Resistant Type 2 Diabetes: Hepatic Steatosis and Fibrosis Indices

    by Makoto Miyabayashi, Masaya Koshizaka, Mayumi Shoji, Hiyori Kaneko, Kazuto Aono, Hisaya Kato, Tetta Sato, Takuro Horikoshi, Mai Ishikawa, Akiko Sekiguchi, et al.

    Aim: This study compared metabolic dysfunction‐associated steatotic liver disease (MASLD) in individuals with Werner syndrome (WS) and individuals with insulin‐resistant type 2 diabetes (T2D). It also examined the association with imaging findings of MASLD in individuals with WS, clarified the characteristics of MASLD that accompany WS, and identified useful indices for its diagnosis in addition to imaging. Methods: Three hepatic steatosis and two hepatic fibrosis indices in 48 individuals enrolled in the Japanese Werner Syndrome Registry were compared with those in 101 Japanese individuals with insulin‐resistant T2D from another clinical study. In individuals with WS, the liver/spleen ratio (L/S ratio) was calculated from computed tomography (CT) images, and its associations with each index were examined. Statistical analyses were performed using the Welch test and pairwise comparisons. Results: Individuals with WS had lower hepatic steatosis and fibrosis index values than those with insulin‐resistant T2D. The mean L/S ratio calculated from CT images was 1.05 ± 0.24 in individuals with WS. The L/S ratio, which is one of the indicators for diagnosing MASLD, was < 0.9 in 5 of 20 cases (25%). Among the various indices in individuals with WS, only the hepatic steatosis index (HSI) was correlated with the L/S ratio ( r = −0.863, p = 0.0003). Conclusions: The prevalence of MASLD is lower in individuals with WS than in those with insulin‐resistant T2D. The HSI was associated with the L/S ratio in individuals with WS, suggesting that HSI may reflect hepatic steatosis‐related changes in this population. Further studies in larger cohorts are needed to validate these findings. Trial Registration: The study was registered at the UMIN Clinical Trial Registry ( https://upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000034058 ) on November 3, 2017 (ID: UMIN000029812)

  • Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial

    by Toshiki Sakai, Ryoichi Ishibashi, Masaya Koshizaka, Yoko Takatsuna, Tomoaki Tatsumi, Takayuki Baba, Kenichi Sakurai, Yoshiro Maezawa, Koutaro Yokote

    Aims: To evaluate whether intravitreal ranibizumab (IVR) frequency is associated with longitudinal renal markers in diabetic macular oedema (DMO) and whether the expected systemic renal and haematological effects of SGLT2 inhibition are reproduced. Materials and Methods: In this post hoc sub‐analysis of the prospective COMET randomised controlled trial, 53 participants were analysed. The estimated glomerular filtration rate (eGFR), haematocrit (Hct), and urinary albumin‐to‐creatinine ratio (UACR) were assessed over 48 weeks using linear mixed‐effects models with the treatment group, week, group‐by‐week interaction, and cumulative IVR as fixed effects. Results: Baseline eGFR was preserved (72.2 ± 18.5 mL/min/1.73 m 2 ) despite common albuminuria (median UACR 50.6 mg/gCr); mean cumulative IVR at week 48 was 7.00 ± 4.42. Cumulative IVR was not significantly associated with eGFR (−0.22 mL/min/1.73 m 2 per injection; 95% CI −0.59 to 0.15; p = 0.25), ln(UACR), or Hct. The SGLT2 inhibitor reproduced an early eGFR dip and Hct rise. Conclusions: No statistically significant exposure‐response association was detected between cumulative IVR and renal markers within the COMET trial cohort and dosing range. Because all participants received IVR and the sample size was modest, small cumulative renal effects cannot be excluded. Trial Registration: University Hospital Medical Information Network Center (UMIN000057674); Japan Registry of Clinical Trials (jRCTs031180210, parent COMET trial)

  • Sodium–Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage‐Dependent Systemic‐Retinal Responsiveness

    by Ryoichi Ishibashi, Kiichi Hirayama, Toshiki Sakai, Tomoaki Tatsumi, Yoko Takatsuna, Takayuki Baba, Masaya Koshizaka, Koutaro Yokote

    Aims: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors exert systemic cardiometabolic, renal and vascular effects that may influence retinal health, yet whether their effects on diabetic macular oedema (DMO) are stage‐dependent remains unclear. We synthesized real‐world, interventional and mechanistic evidence on responsiveness across disease stages and retinal phenotypes. Materials and Methods: In this scoping review (PRISMA‐ScR; prospectively registered, UMIN000061304), we searched PubMed, the Cochrane Library, ClinicalTrials.gov , WHO‐ICTRP and Google Scholar for studies published from January 2014 to April 2026. Two reviewers independently screened and charted records. Heterogeneity precluded meta‐analysis, so a qualitative meta‐summary with exploratory E‐value analyses was performed. Results: Forty studies were included. Large administrative databases consistently associated SGLT2 inhibitor use with a 16%–35% lower DMO incidence (hazard ratio 0.65–0.84) and hazard ratios of 0.53–0.94 for diabetic retinopathy progression. In established DMO, observational studies reported hazard ratios of 0.39–0.81 for anti‐vascular endothelial growth factor (VEGF) injections, corticosteroid therapy and repeat vitrectomy, with the first‐vitrectomy estimate non‐significant, and attenuation in severe non‐proliferative or proliferative retinopathy. The only randomized trial (COMET) did not meet its primary endpoint; its fellow‐eye and phenotype‐specific subgroup analyses were exploratory and hypothesis‐generating. Proposed mechanisms include suppression of microglial activation, oxidative stress and angiopoietin‐2/VEGF signalling, although translational evidence remains preclinical. Conclusions: This predominantly observational evidence suggests that SGLT2 inhibitors may be associated with slower DMO disease kinetics across retinopathy stages, with reduced treatment burden most evident before severe retinopathy. Systemic SGLT2 inhibition may complement, rather than replace, anti‐VEGF therapy, which remains the cornerstone of DMO management. These findings support prospective stage‐ and phenotype‐stratified investigation.

  • Baseline HDL Cholesterol and the Anti‐ VEGF Injection‐Sparing Effect of an SGLT2 Inhibitor in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial

    by Ryoichi Ishibashi, Masaya Koshizaka, Kiichi Hirayama, Toshiki Sakai, Tomoaki Tatsumi, Yoko Takatsuna, Takayuki Baba, Yoshiro Maezawa, Koutaro Yokote

  • Open Access

    Association of GLP ‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study

    by Masaya Koshizaka, Ryoichi Ishibashi, Tomoki Ishikawa, Kazuo Goda, Jumpei Sato, Masaru Kitsuregawa, Koutaro Yokote, Naohiro Mitsutake

    Aims: Large‐scale clinical trials have shown multiple effects of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs); however, similar evidence for Asian patients is limited. Therefore, using a Japanese large‐scale claims‐based database, the effects of GLP‐1RAs on cardiovascular and cerebrovascular events including mortality were compared with those of other glucose‐lowering agents. Materials and Methods: Patients with type 2 diabetes (T2D) were identified from a claims database of approximately 1.9 million individuals. Those newly prescribed GLP‐1RAs between 2014 and 2021 were assigned to the GLP‐1RA group, while those initiating other glucose‐lowering agents served as controls. The primary outcome was cardiovascular or cerebrovascular events or all‐cause mortality. Logistic regression analysis was performed using explanatory variables, and nearest‐neighbour propensity score matching was performed between the groups. The period from the initiation of new medication to event occurrence was calculated and analysed using the Cox proportional hazards model, with a maximum follow‐up of 38 months. Results: Among 469 461 eligible patients, 2401 received GLP‐1RAs and 53 946 were controls. After propensity matching, 2147 patients remained in each group. The median follow‐up was 12 months. No significant difference was observed in 3‐point major adverse cardiovascular events (3‐point MACE) (GLP‐1RA, 7.08% ( n = 152) versus control, 8.20% ( n = 176); hazard ratio (HR), 0.920; 95% confidence interval (CI) 0.740–1.143, p = 0.450). However, all‐cause mortality was lower in the GLP‐1RAs group (5.36% ( n = 115) versus 7.36% ( n = 158), HR 0.776, 95% CI 0.610–0.987, p = 0.039). Conclusions: GLP‐1RA showed no association with 3‐point MACE difference but showed lower all‐cause mortality. These findings possibly reflect residual confounding.

  • Open Access

    Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial

    by Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Tomoaki Tatsumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote

    Aims: To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular edema (DMO) via post hoc subgroup analysis. Previous findings were derived exclusively from observational studies, and no interventional trials based on protocol‐defined criteria had been conducted. Materials and Methods: Based on the COMET trial data, this post hoc analysis targeted mild DME cases, defined by baseline central retinal thickness (CRT) ≤375 μm and best‐corrected visual acuity (BCVA) ≤0.155 (logMAR). Patients were randomized to SGLT2i (luseogliflozin) or sulfonylurea (SU, glimepiride) groups. Mild subgroups were compared with the corresponding non‐mild cases. The primary outcome was the 48‐week frequency of intravitreal ranibizumab injections (IVRs). Results: In the CRT ≤375 μm subgroup, IVR frequency was significantly lower with SGLT2i vs SU (mean 0.5 ± 1.0 vs 4.3 ± 0.8; P = 0.005, adjusted ancova . Cohen's d of 2.1). The cumulative mean number of IVRs was significantly lower in the SGLT2i group than in the SU group ( P = 0.004, hazard ratio 0.29, 95% confidence interval 0.12–0.67). In the BCVA ≤ 0.155 subgroup, whose mean CRT exceeded 400 μm, no significant difference in IVR frequency was observed between the SGLT2i‐treated and SU‐treated patients. In addition, no intergroup differences were found in patients outside the mild subgroups. Conclusions: In this exploratory analysis, SGLT2 inhibition was associated with fewer intravitreal injections in patients meeting the CRT‐based mild criteria. These findings are hypothesis‐generating and warrant confirmation in future prospective studies.


  • Ophthalmic Backgrounds Influencing the Efficacy of SGLT2 Inhibitor in Diabetic Macular Oedema: Post‐hoc Analysis of the COMET Trial

    by Ryoichi Ishibashi, Tomoaki Tatsumi, Masaya Koshizaka, Yoko Takatsuna, Tomomi Kaiho, Yosuke Nakamura, Noriko Asaumi, Kiichi Hirayama, Takayuki Baba, Koutaro Yokote


  • Open Access

    Study of weight loss intervention to find an effective strategy for obesity management and the TARGET of weight loss amount for reducing health disorders (SLIM-TARGET): a randomized controlled trial

    by Masaya Koshizaka, Hidetaka Yokoh, Ko Ishikawa, Aiko Hayashi, Yukari Maeda, Jin Kumagai, Kenji Takeda, Hiyori Kaneko, Tomohiro Ohno, Hiraku Ono, et al.

    This randomized controlled study aimed to clarify weight loss targets for improving obesity-related disorders in individuals with overweight or obesity. A total of 294 participants with six obesity-related conditions were assigned to either a standard or intensive treatment group, with 12-month weight loss targets of ≥3% and ≥7%, respectively. The standard group followed the Japanese Guidelines for the Management of Obesity Disease 2016. The intensive group received frequent nutritional guidance, enhanced diet and exercise therapy, and additional pharmacotherapy. The primary outcome was weight loss and improvement in at least two obesity-related disorders at 12 months. Secondary outcomes included remission of health disorders, improvement in at least one health disorder, and visceral fat reduction. At 12 months, the weight loss was –2.5% in the intensive group and –1.7% in the standard group, with no significant difference in the primary outcome. However, remission of health disorders was achieved in 16.9% of the intensive group compared with 6.2% of the standard group (adjusted odds ratio 3.079; 95% CI 1.075–8.823; p = 0.036). Visceral fat reduction was greater in the intensive group (–20.46 cm2 vs. –8.9 cm2; p = 0.039). Intensive treatment significantly improved blood pressure early and increased treatment motivation scores by 10.9% (95% CI: 1.2–20.6) at 24 months (p = 0.004). In both groups, ≥60% of the participants showed improvement in at least one disorder. Despite not achieving the target weight loss, resulting in no significant difference in the primary outcome, the intensive treatment increased remission percentages, improved early blood pressure control, and enhanced long-term treatment motivation. The study was registered at UMIN Clinical Trials Registry (UMIN ID: UMIN000031862).

  • Open Access

    Blood Pressure Status Modulates the Therapeutic Response to Sodium‐Glucose Cotransporter 2 Inhibitors in Diabetic Macular Edema: A Post Hoc Subgroup Analysis of the COMET Trial

    by Ryoichi Ishibashi, Masaya Koshizaka, Yoko Takatsuna, Tomoaki Tatsumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote

    Aims: To evaluate the feasibility of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) as a systemic adjunct for patients with diabetic macular edema (DME) and hypertension. Materials and Methods: This study encompassed a post hoc analysis of the COMET Trial data, focusing on patients with DME and hypertension, defined by office systolic blood pressure (OSBP) ≥ 140 mmHg or a documented history of hypertension. Participants were randomized to receive either SGLT2i (luseogliflozin) or sulfonylurea (SU, glimepiride). The primary outcome was the treatment burden, quantified by the total number of intravitreal ranibizumab injections (IVRs) over 48 weeks. Results: Within the OSBP ≥ 140 mmHg subgroup, 14 patients received SGLT2i and 15 received SU. The total number of IVRs was 4.1 ± 3.1 in the SGLT2i group and 6.8 ± 3.1 in the SU group (Cohen's d = 0.87; power = 0.82). The adjusted analysis of covariance further confirmed significantly fewer IVRs in the SGLT2i group (3.3 ± 1.1 vs. 6.2 ± 1.0, p = 0.025). OSBP was significantly reduced in the SGLT2i group at Week 12, but there was no significant difference at Week 48. Office diastolic blood pressure remained consistently lower in the SGLT2i group. No significant differences in IVR frequency were observed in other subgroups. Conclusions: SGLT2i may help reduce the treatment burden of IVRs in patients with DME and elevated OSBP. The improvements in blood pressure and visual acuity, despite fewer injections, indicate a potential synergistic effect of SGLT2i in managing DME with hypertension. Further investigation is warranted to validate its efficacy as a potential systemic adjunct. Trial Registration: UMIN000057674.


  • Emerging strategies, applications and challenges of targeting NAD+ in the clinic

    by Jianying Zhang, He-Ling Wang, Sofie Lautrup, Hilde Loge Nilsen, Jonas T. Treebak, Leiv Otto Watne, Geir Selbæk, Lindsay E. Wu, Torbjørn Omland, Eija Pirinen, et al.

    Beyond their classical functions as redox cofactors, recent fundamental and clinical research has expanded our understanding of the diverse roles of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) in signaling pathways, epigenetic regulation and energy homeostasis. Moreover, NAD and NADP influence numerous diseases as well as the processes of aging, and are emerging as targets for clinical intervention. Here, we summarize safety, bioavailability and efficacy data from NAD+-related clinical trials, focusing on aging and neurodegenerative diseases. We discuss the established NAD+ precursors nicotinic acid and nicotinamide, newer compounds such as nicotinamide riboside and nicotinamide mononucleotide, and emerging precursors. We also discuss technological advances including in industrial-scale production and real-time detection, which are facilitating NAD+ research and clinical translation. Finally, we emphasize the need for further large-scale studies to determine optimal dose, administration routes and frequency, as well as long-term safety and interindividual variability in response.